tiprankstipranks
Allogene Therapeutics Inc (ALLO)
NASDAQ:ALLO
US Market
ALLO
Allogene Therapeutics
RESEARCH TOOLSreports
Want to see ALLO full AI Analyst Report?

Allogene Therapeutics (ALLO) Stock Forecast & Price Target

1,750 Followers
See the Price Targets and Ratings of:

ALLO Analyst Ratings

Strong Buy
14Ratings
Strong Buy
12 Buy
2 Hold
0 Sell
Based on 14 analysts giving stock ratings to
Allogene
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ALLO Stock 12 Month Forecast

Average Price Target

$8.71
▲(264.59% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for Allogene Therapeutics in the last 3 months. The average price target is $8.71 with a high forecast of $14.00 and a low forecast of $3.85. The average price target represents a 264.59% change from the last price of $2.39.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","15":"$15","3.75":"$3.75","7.5":"$7.5","11.25":"$11.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.713636363636363,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.85,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.85</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.75,7.5,11.25,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.56,3.44,4.32,5.2,6.08,6.960000000000001,7.84,8.72,9.6,10.48,11.360000000000001,12.24,13.120000000000001,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.56,3.0333566433566435,3.5067132867132864,3.98006993006993,4.453426573426573,4.926783216783217,5.400139860139859,5.8734965034965025,6.346853146853146,6.820209790209789,7.293566433566433,7.766923076923076,8.24027972027972,{"y":8.713636363636363,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.56,2.6592307692307693,2.7584615384615385,2.8576923076923078,2.956923076923077,3.056153846153846,3.1553846153846155,3.2546153846153847,3.353846153846154,3.453076923076923,3.5523076923076924,3.6515384615384616,3.750769230769231,{"y":3.85,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.37,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.69,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.27,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.08,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.12,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.37,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.37,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.87,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.65,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.56,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$14.00Average Price Target$8.71Lowest Price Target$3.85
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on ALLO
Biren Amin
Piper Sandler
Piper Sandler
$8→$10
Buy
318.41%
Upside
Reiterated
04/22/26
Analysts Are Bullish on Top Healthcare Stocks: Merck & Company (MRK), Allogene Therapeutics (ALLO)
H.C. Wainwright Analyst forecast on ALLO
Robert Burns
H.C. Wainwright
H.C. Wainwright
$12→$11
Buy
360.25%
Upside
Reiterated
04/16/26
Allogene Therapeutics price target raised to $12 from $8 at H.C. WainwrightAllogene Therapeutics price target raised to $12 from $8 at H.C. Wainwright
J.P. Morgan Analyst forecast on ALLO
Brian Cheng
J.P. Morgan
J.P. Morgan
―
Hold
―
Upgraded
04/16/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Allogene Therapeutics (NASDAQ: ALLO), Phathom Pharmaceuticals (NASDAQ: PHAT) and BioMarin Pharmaceutical (NASDAQ: BMRN)
Jefferies Analyst forecast on ALLO
Roger Song
Jefferies
Jefferies
$6→$10
Buy
318.41%
Upside
Reiterated
04/15/26
Allogene Therapeutics price target raised to $10 from $6 at JefferiesAllogene Therapeutics price target raised to $10 from $6 at Jefferies
Canaccord Genuity Analyst forecast on ALLO
John Newman
Canaccord Genuity
Canaccord Genuity
$14
Buy
485.77%
Upside
Reiterated
04/14/26
Canaccord Genuity Keeps Their Buy Rating on Allogene Therapeutics (ALLO)
Bernstein Analyst forecast on ALLO
William Pickering
Bernstein
Bernstein
$1.6→$3.85
Hold
61.09%
Upside
Reiterated
04/14/26
Bernstein Sticks to Their Hold Rating for Allogene Therapeutics (ALLO)
Citizens JMP Analyst forecast on ALLO
Reni Benjamin
Citizens JMP
Citizens JMP
$5→$8
Buy
234.73%
Upside
Reiterated
04/14/26
Allogene Therapeutics price target raised to $8 from $5 at CitizensAllogene Therapeutics price target raised to $8 from $5 at Citizens
Robert W. Baird Analyst forecast on ALLO
Jack Allen
Robert W. Baird
Robert W. Baird
$7→$9
Buy
276.57%
Upside
Reiterated
04/14/26
Allogene Therapeutics price target raised to $9 from $7 at BairdAllogene Therapeutics price target raised to $9 from $7 at Baird
TD Cowen Analyst forecast on ALLO
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
04/13/26
Allogene Therapeutics data from ALPHA3 trial a 'home run,' says TD CowenAllogene Therapeutics data from ALPHA3 trial a 'home run,' says TD Cowen
William Blair Analyst forecast on ALLO
Sami Corwin
William Blair
William Blair
―
Buy
―
Reiterated
04/13/26
Allogene Therapeutics: Strong ALPHA3 Futility Data and Favorable Safety Profile Support Buy Rating and Blockbuster Potential for Cema-cel in LBCL
Citi Analyst forecast on ALLO
Samantha Semenkow
Citi
Citi
$4
Buy
67.36%
Upside
Assigned
04/09/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Oppenheimer Analyst forecast on ALLO
Matthew Biegler
Oppenheimer
Oppenheimer
$7
Buy
192.89%
Upside
Reiterated
03/13/26
Analysts Are Bullish on Top Healthcare Stocks: Insulet (PODD), Pliant Therapeutics (PLRX)
Truist Financial Analyst forecast on ALLO
Asthika Goonewardene
Truist Financial
Truist Financial
$10
Buy
318.41%
Upside
Reiterated
03/13/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
RBC Capital Analyst forecast on ALLO
Luca Issi
RBC Capital
RBC Capital
$9
Buy
276.57%
Upside
Reiterated
03/12/26
RBC Capital Keeps Their Buy Rating on Allogene Therapeutics (ALLO)
UBS Analyst forecast on ALLO
Michael Yee
UBS
UBS
$8
Buy
234.73%
Upside
Initiated
01/06/26
Allogene Therapeutics initiated with a Buy at UBSAllogene Therapeutics initiated with a Buy at UBS
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on ALLO
Biren Amin
Piper Sandler
Piper Sandler
$8→$10
Buy
318.41%
Upside
Reiterated
04/22/26
Analysts Are Bullish on Top Healthcare Stocks: Merck & Company (MRK), Allogene Therapeutics (ALLO)
H.C. Wainwright Analyst forecast on ALLO
Robert Burns
H.C. Wainwright
H.C. Wainwright
$12→$11
Buy
360.25%
Upside
Reiterated
04/16/26
Allogene Therapeutics price target raised to $12 from $8 at H.C. WainwrightAllogene Therapeutics price target raised to $12 from $8 at H.C. Wainwright
J.P. Morgan Analyst forecast on ALLO
Brian Cheng
J.P. Morgan
J.P. Morgan
―
Hold
―
Upgraded
04/16/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Allogene Therapeutics (NASDAQ: ALLO), Phathom Pharmaceuticals (NASDAQ: PHAT) and BioMarin Pharmaceutical (NASDAQ: BMRN)
Jefferies Analyst forecast on ALLO
Roger Song
Jefferies
Jefferies
$6→$10
Buy
318.41%
Upside
Reiterated
04/15/26
Allogene Therapeutics price target raised to $10 from $6 at JefferiesAllogene Therapeutics price target raised to $10 from $6 at Jefferies
Canaccord Genuity Analyst forecast on ALLO
John Newman
Canaccord Genuity
Canaccord Genuity
$14
Buy
485.77%
Upside
Reiterated
04/14/26
Canaccord Genuity Keeps Their Buy Rating on Allogene Therapeutics (ALLO)
Bernstein Analyst forecast on ALLO
William Pickering
Bernstein
Bernstein
$1.6→$3.85
Hold
61.09%
Upside
Reiterated
04/14/26
Bernstein Sticks to Their Hold Rating for Allogene Therapeutics (ALLO)
Citizens JMP Analyst forecast on ALLO
Reni Benjamin
Citizens JMP
Citizens JMP
$5→$8
Buy
234.73%
Upside
Reiterated
04/14/26
Allogene Therapeutics price target raised to $8 from $5 at CitizensAllogene Therapeutics price target raised to $8 from $5 at Citizens
Robert W. Baird Analyst forecast on ALLO
Jack Allen
Robert W. Baird
Robert W. Baird
$7→$9
Buy
276.57%
Upside
Reiterated
04/14/26
Allogene Therapeutics price target raised to $9 from $7 at BairdAllogene Therapeutics price target raised to $9 from $7 at Baird
TD Cowen Analyst forecast on ALLO
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
04/13/26
Allogene Therapeutics data from ALPHA3 trial a 'home run,' says TD CowenAllogene Therapeutics data from ALPHA3 trial a 'home run,' says TD Cowen
William Blair Analyst forecast on ALLO
Sami Corwin
William Blair
William Blair
―
Buy
―
Reiterated
04/13/26
Allogene Therapeutics: Strong ALPHA3 Futility Data and Favorable Safety Profile Support Buy Rating and Blockbuster Potential for Cema-cel in LBCL
Citi Analyst forecast on ALLO
Samantha Semenkow
Citi
Citi
$4
Buy
67.36%
Upside
Assigned
04/09/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Oppenheimer Analyst forecast on ALLO
Matthew Biegler
Oppenheimer
Oppenheimer
$7
Buy
192.89%
Upside
Reiterated
03/13/26
Analysts Are Bullish on Top Healthcare Stocks: Insulet (PODD), Pliant Therapeutics (PLRX)
Truist Financial Analyst forecast on ALLO
Asthika Goonewardene
Truist Financial
Truist Financial
$10
Buy
318.41%
Upside
Reiterated
03/13/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
RBC Capital Analyst forecast on ALLO
Luca Issi
RBC Capital
RBC Capital
$9
Buy
276.57%
Upside
Reiterated
03/12/26
RBC Capital Keeps Their Buy Rating on Allogene Therapeutics (ALLO)
UBS Analyst forecast on ALLO
Michael Yee
UBS
UBS
$8
Buy
234.73%
Upside
Initiated
01/06/26
Allogene Therapeutics initiated with a Buy at UBSAllogene Therapeutics initiated with a Buy at UBS
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Allogene Therapeutics

3 Months
xxx
Success Rate
9/20 ratings generated profit
45%
Average Return
-2.30%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 45.00% of your transactions generating a profit, with an average return of -2.30% per trade.
1 Year
John NewmanCanaccord Genuity
Success Rate
10/27 ratings generated profit
37%
Average Return
-5.08%
Copying John Newman's trades and holding each position for 1 Year would result in 37.04% of your transactions generating a profit, with an average return of -5.08% per trade.
2 Years
xxx
Success Rate
8/18 ratings generated profit
44%
Average Return
-3.49%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 44.44% of your transactions generating a profit, with an average return of -3.49% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ALLO Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
6
8
2
8
12
Buy
2
3
3
5
7
Hold
0
0
0
0
2
Sell
2
0
0
0
0
Strong Sell
0
0
0
0
0
total
10
11
5
13
21
In the current month, ALLO has received 19 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. ALLO average Analyst price target in the past 3 months is 8.71.
Each month's total comprises the sum of three months' worth of ratings.

ALLO Financial Forecast

ALLO Earnings Forecast

Next quarter’s earnings estimate for ALLO is -$0.19 with a range of -$0.22 to -$0.17. The previous quarter’s EPS was -$0.17. ALLO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ALLO has Performed in-line its overall industry.
Next quarter’s earnings estimate for ALLO is -$0.19 with a range of -$0.22 to -$0.17. The previous quarter’s EPS was -$0.17. ALLO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ALLO has Performed in-line its overall industry.

ALLO Sales Forecast

Next quarter’s sales forecast for ALLO is $2.00K with a range of $0.00 to $20.00K. The previous quarter’s sales results were $0.00. ALLO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ALLO has Performed in-line its overall industry.
Next quarter’s sales forecast for ALLO is $2.00K with a range of $0.00 to $20.00K. The previous quarter’s sales results were $0.00. ALLO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ALLO has Performed in-line its overall industry.

ALLO Stock Forecast FAQ

What is ALLO’s average 12-month price target, according to analysts?
Based on analyst ratings, Allogene Therapeutics Inc’s 12-month average price target is 8.71.
    What is ALLO’s upside potential, based on the analysts’ average price target?
    Allogene Therapeutics Inc has 264.59% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ALLO a Buy, Sell or Hold?
          Allogene Therapeutics Inc has a consensus rating of Strong Buy which is based on 12 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Allogene Therapeutics Inc’s price target?
            The average price target for Allogene Therapeutics Inc is 8.71. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $14.00 ,the lowest forecast is $3.85. The average price target represents 264.59% Increase from the current price of $2.39.
              What do analysts say about Allogene Therapeutics Inc?
              Allogene Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of ALLO?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.